Aveo Pharmaceuticals Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financi

Gainers Volt Information Sciences, Inc. (NYSE: VOLT ) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex Healthcare Limited (NASDAQ: IXHL ) surged 54% to settle at $22.90. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA). Red Cat Holdings, Inc. (NASDAQ: RCAT ) rose 48.4% to close at $2.73 after the company announced its subsidiary Teal Drones has been selected by the Department of Defense''s Defense Innovation Unit and U.S. Army to compete in the Short Range Reconnaissance Tranche 2 Program of Record. Q&K International Group Limited (NASDAQ: QK ) jumped 37.6% to settle at $1.6920. Q&K shares recently announced an ADS ratio change. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) shares gained 25.7% to close at $3.96. Turquoise Hill Resources Ltd. (NYSE: TRQ ) jumped 31.9% to settle at $26.55 after Rio Tinto proposed to acquire the company at C$34 per share.

AVEO Pharmaceuticals Inc's (AVEO) CEO Michael Bailey on Q4 2021 Results - Earnings Call Transcript

AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals press release (AVEO): Q4 GAAP EPS of -$0.21 beats by $0.07.Revenue of $17.65M (+1883.1% Y/Y) misses by $0.7M.AVEO believes that its $87.3 million in cash,…

– Total 2021 Net Revenue of $42.3 Million –

AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) delivered earnings and revenue surprises of -25% and 0%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial r

Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?